Get started
Author

Marco Sanduzzi‐Zamparelli

Observed names: M Sanduzzi-Zamparelli, M. Sanduzzi Zamparelli, M. Sanduzzi-Zamparelli, M., SanduzziZamparelli, Marco Sanduzzi Zamparelli, Marco Sanduzzi-Zamparelli, Sanduzzi Zamparelli, Marco, Sanduzzi-Zamparelli, Marco
Observed institutions: Instituto de Salud Carlos III, Ospedale Antonio Cardarelli, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, Federico II University Hospital, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Fundació Clínic per a la Recerca Biomèdica, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Naples Federico II, Universitat de Barcelona
ORCID: 0000-0003-3795-3705
Observed ORCID: 0000-0003-3795-3705
OpenAlex ID: A5004046885
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
2025 · Maria Reig, Marco Sanduzzi-Zamparelli, et al. · Journal of Hepatology · 222
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression
2021 · Lorenzo A. Orci, Marco Sanduzzi-Zamparelli, et al. · Clinical Gastroenterology and Hepatology · 217
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
2024 · Ignacio Melero, Maria de Miguel Luken, et al. · Nature · 128
PDF
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection
2024 · Carla Fuster-Anglada, Ezequiel Mauro, et al. · Journal of Hepatology · 123
International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance
2023 · Amit G. Singal, Marco Sanduzzi-Zamparelli, et al. · Journal of Hepatology · 95
May Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence
2020 · Giuseppe Annunziata, Marco Sanduzzi Zamparelli, et al. · Frontiers in Medicine · 92
PDF
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
2019 · Massimo Iavarone, Federica Invernizzi, et al. · American Journal of Transplantation · 87
PDF
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study
2023 · Elianet Fonseca, Jose M Cabrera-Maqueda, et al. · The Lancet Neurology · 63
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
2021 · Sergio Muñoz-Martínez, Victor Sapena, et al. · JHEP Reports · 63
The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma
2017 · Marco Sanduzzi Zamparelli, Alba Rocco, et al. · United European Gastroenterology Journal · 62
PDF
Controversies in the management of hepatocellular carcinoma
2019 · Alejandro Forner, Leonardo G Da Fonseca, et al. · JHEP Reports · 59
PDF
The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
2016 · Marco Sanduzzi Zamparelli, Debora Compare, et al. · International Journal of Molecular Sciences · 59
PDF
The Gut Bacteria-Driven Obesity Development
2016 · Debora Compare, Alba Rocco, et al. · Digestive Diseases · 59
Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib
2019 · Álvaro Díaz‐González, Marco Sanduzzi‐Zamparelli, et al. · Alimentary Pharmacology & Therapeutics · 44
PDF
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
2021 · Marco Sanduzzi-Zamparelli, Zoe Mariño, et al. · Journal of Hepatology · 41
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study
2021 · Massimo Iavarone, Federica Invernizzi, et al. · Liver Transplantation · 37
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
2023 · Ismael El Hajra, Marco Sanduzzi-Zamparelli, et al. · Hepatology · 35
PDF
New Systemic Treatments in Advanced Hepatocellular Carcinoma
2018 · Marco Sanduzzi‐Zamparelli, Álvaro Díaz‐Gonzalez, et al. · Liver Transplantation · 28
Hepatic epithelioid hemangioendothelioma: An international multicenter study
2020 · Marco Sanduzzi-Zamparelli, Jordi Rimola, et al. · Digestive and Liver Disease · 26
Current pharmacological treatment of hepatocellular carcinoma
2021 · Sergio Muñoz-Martínez, Gemma Iserte, et al. · Current Opinion in Pharmacology · 23
PDF
Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
2019 · Marco Sanduzzi-Zamparelli, Loreto Boix, et al. · Viruses · 21
PDF
Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
2022 · Sergio Muñoz‐Martínez, Victor Sapena, et al. · Liver International · 20
PDF
International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis
2020 · Álvaro Díaz‐González, Marco Sanduzzi‐Zamparelli, et al. · Liver International · 19
PDF
Challenges in Liver Transplantation for Hepatocellular Carcinoma: A Review of Current Controversies
2024 · Ezequiel Mauro, Marco Sanduzzi-Zamparelli, et al. · Cancers · 14
PDF
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials
2020 · Álvaro Díaz‐González, Víctor Sapena, et al. · Liver International · 13
Works count: 81
Citation count: 1,783
H-index: 21
I10-index: 27
Year
Topic
Type